Tirzepatide Quick Start
Disclaimer
This page is an educational research and dosing reference. It is not medical advice and does not replace guidance from a licensed clinician. Tirzepatide carries a boxed warning for thyroid C-cell tumors. Tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Tirzepatide is a once-weekly injection that activates two appetite and blood-sugar hormones at the same time: GIP and GLP-1. The single-target competitor most people know is semaglutide (Ozempic, Wegovy), which only activates GLP-1. Retatrutide goes one step further by adding glucagon receptor activity, but it remains investigational. Tirzepatide activates both GIP and GLP-1, which is why it is called a dual agonist.
Mounjaro and Zepbound contain tirzepatide, but their prescribing instructions differ. Mounjaro is approved for type 2 diabetes from age 10 and to reduce major cardiovascular events in adults with type 2 diabetes at high risk. Zepbound is approved for adult weight reduction and long-term maintenance, and for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Use the label for the exact brand, indication, and age group.
Route
Subcutaneous (under-the-skin) injection, once per week, on the same day each week.
Dose ladder
Adult Zepbound example: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly. Later increases are optional, with at least 4 weeks at the current dose.
Measure
At an assumed 20 mg/mL, 1 mg equals 0.05 mL or 5 U-100 units. This is research-vial arithmetic, not a preparation or prescribing instruction.
Supplies
Research-vial supply totals are arithmetic only. Actual quantities depend on validated product-specific storage, discard dates, and losses.
Research status
FDA-approved drug as Mounjaro/Zepbound. Lyophilized research-use vials are a separate, non-FDA grey-market supply.
Mounjaro vs Zepbound at a glance
Tirzepatide labels by product and patient group (October 2026)
Active drug
Mounjaro
Tirzepatide
Zepbound
Tirzepatide
FDA indication
Mounjaro
Type 2 diabetes from age 10; major cardiovascular-event risk reduction in high-risk adults with T2D
Zepbound
Adult weight reduction and long-term maintenance; moderate-to-severe OSA in adults with obesity
First approved
Mounjaro
May 2022
Zepbound
November 2023
Dose selection
Mounjaro
Start at 2.5 mg weekly; increase by 2.5 mg after at least 4 weeks if additional glycemic control is needed
Zepbound
2.5 mg weekly for 4 weeks, then 5 mg; further 2.5 mg increases after at least 4 weeks as needed
Maintenance and maximum
Mounjaro
Adult maximum 15 mg weekly; ages 10–17 maximum 10 mg weekly. Adult maintenance is not restricted to 5/10/15 mg
Zepbound
Weight: 5, 10, or 15 mg weekly. OSA: 10 or 15 mg weekly. Adult maximum 15 mg
| Mounjaro | Zepbound | |
|---|---|---|
| Active drug | Tirzepatide | Tirzepatide |
| FDA indication | Type 2 diabetes from age 10; major cardiovascular-event risk reduction in high-risk adults with T2D | Adult weight reduction and long-term maintenance; moderate-to-severe OSA in adults with obesity |
| First approved | May 2022 | November 2023 |
| Dose selection | Start at 2.5 mg weekly; increase by 2.5 mg after at least 4 weeks if additional glycemic control is needed | 2.5 mg weekly for 4 weeks, then 5 mg; further 2.5 mg increases after at least 4 weeks as needed |
| Maintenance and maximum | Adult maximum 15 mg weekly; ages 10–17 maximum 10 mg weekly. Adult maintenance is not restricted to 5/10/15 mg | Weight: 5, 10, or 15 mg weekly. OSA: 10 or 15 mg weekly. Adult maximum 15 mg |
Sources: current Lilly Mounjaro and Zepbound prescribing information. Zepbound’s maintenance choices do not define Mounjaro dosing, and the adult maximum does not apply to pediatric Mounjaro use.
Tirzepatide Dosing Protocol & Schedule
The table below is an adult Zepbound example showing the earliest possible timing of each step. It is not a requirement to reach 15 mg. Zepbound starts at 2.5 mg weekly for 4 weeks, then 5 mg; later 2.5 mg increases may occur after at least 4 weeks at the current dose, based on response and tolerability. Weight-reduction maintenance is 5, 10, or 15 mg; OSA maintenance is 10 or 15 mg. The adult maximum is 15 mg weekly. Zepbound prescribing information, sections 2.1–2.2.
Tirzepatide Dosing Schedule
The first tab summarizes adult Zepbound labeling. The second is separate nominal research-vial arithmetic; it does not transfer an approved regimen to a research product.
Earliest escalation example for adults prescribed Zepbound; later increases depend on clinical response and tolerability.
Adult Zepbound escalation example (earliest timing)
Step
Phase 1 — Initiation
Earliest weeks
Weeks 1–4
Weekly dose
2.5 mg once weekly
Label context
Initiation dose; not an approved Zepbound maintenance dose.
Step
Phase 2 — 5 mg step
Earliest weeks
Weeks 5–8
Weekly dose
5 mg once weekly
Label context
Weight-reduction maintenance option; not an OSA maintenance dose.
Step
Phase 3 — Mid escalation
Earliest weeks
Weeks 9–12
Weekly dose
7.5 mg once weekly
Label context
Optional escalation step after at least 4 weeks at 5 mg.
Step
Phase 4 — 10 mg step
Earliest weeks
Weeks 13–16
Weekly dose
10 mg once weekly
Label context
Maintenance option for weight reduction and OSA.
Step
Phase 5 — High escalation
Earliest weeks
Weeks 17–20
Weekly dose
12.5 mg once weekly
Label context
Optional escalation step after at least 4 weeks at 10 mg.
Step
Phase 6 — Maximum dose
Earliest weeks
Weeks 21+
Weekly dose
15 mg once weekly
Label context
Adult maximum; maintenance option for weight reduction and OSA.
| Step | Earliest weeks | Weekly dose | Label context |
|---|---|---|---|
| Phase 1 — Initiation | Weeks 1–4 | 2.5 mg once weekly | Initiation dose; not an approved Zepbound maintenance dose. |
| Phase 2 — 5 mg step | Weeks 5–8 | 5 mg once weekly | Weight-reduction maintenance option; not an OSA maintenance dose. |
| Phase 3 — Mid escalation | Weeks 9–12 | 7.5 mg once weekly | Optional escalation step after at least 4 weeks at 5 mg. |
| Phase 4 — 10 mg step | Weeks 13–16 | 10 mg once weekly | Maintenance option for weight reduction and OSA. |
| Phase 5 — High escalation | Weeks 17–20 | 12.5 mg once weekly | Optional escalation step after at least 4 weeks at 10 mg. |
| Phase 6 — Maximum dose | Weeks 21+ | 15 mg once weekly | Adult maximum; maintenance option for weight reduction and OSA. |
Each increase after 5 mg is optional and requires at least 4 weeks at the current dose. Weight maintenance: 5/10/15 mg; OSA: 10/15 mg. Mounjaro has separate indication and age-specific guidance. These are prescribing-information examples, not research-vial instructions.
Missed dose
Per the Mounjaro and Zepbound prescribing information, if a dose is missed it should be administered as soon as possible within 4 days (96 hours). After that window, skip the missed dose and resume on the next regularly scheduled day. Do not double up.
Nominal mass-to-volume conversions only. Research powders are not established as equivalent to Mounjaro or Zepbound.
For an arithmetic example, a nominal 40 mg in a final 2.0 mL gives 20 mg/mL. The reference amounts below do not establish a human regimen, appropriate diluent, sterile preparation, or product equivalence. Research-grade powders are not FDA-approved medicines.
Mg → Units (40 mg vial + 2.0 mL BAC water = 20 mg/mL)
Reference amount
2.5 mg
Calculated volume
0.125 mL
U-100 volume units
12.5 units
Reference amount
5 mg
Calculated volume
0.25 mL
U-100 volume units
25 units
Reference amount
7.5 mg
Calculated volume
0.375 mL
U-100 volume units
37.5 units
Reference amount
10 mg
Calculated volume
0.50 mL
U-100 volume units
50 units
Reference amount
12.5 mg
Calculated volume
0.625 mL
U-100 volume units
62.5 units
Reference amount
15 mg
Calculated volume
0.75 mL
U-100 volume units
75 units
| Reference amount | Calculated volume | U-100 volume units |
|---|---|---|
| 2.5 mg | 0.125 mL | 12.5 units |
| 5 mg | 0.25 mL | 25 units |
| 7.5 mg | 0.375 mL | 37.5 units |
| 10 mg | 0.50 mL | 50 units |
| 12.5 mg | 0.625 mL | 62.5 units |
| 15 mg | 0.75 mL | 75 units |
At this concentration, the 12.5 mg and 15 mg calculated volumes exceed a 0.5 mL syringe. U-100 units measure volume, not drug potency; this table is not administration guidance.
Calculator
For any vial size or BAC-water volume, use the PepPal reconstitution calculator. Enter vial mg, water volume, and target dose to get exact syringe units.
Research-use only
Research-grade vials are sold for laboratory research, not for human use. An FDA-approved indication does not make a research-grade vial approved or suitable for treatment.
Tirzepatide weight-loss dose-tier guide
SURMOUNT-1 primary treatment-regimen results (obesity without diabetes, 72 weeks)
Weekly dose
5 mg
Average weight loss
−15.0%
Plain-English read
5 mg assigned target; not a prediction for an individual.
Weekly dose
10 mg
Average weight loss
−19.5%
Plain-English read
10 mg assigned target; not a required escalation step.
Weekly dose
15 mg
Average weight loss
−20.9%
Plain-English read
15 mg assigned target; adult label maximum.
| Weekly dose | Average weight loss | Plain-English read |
|---|---|---|
| 5 mg | −15.0% | 5 mg assigned target; not a prediction for an individual. |
| 10 mg | −19.5% | 10 mg assigned target; not a required escalation step. |
| 15 mg | −20.9% | 15 mg assigned target; adult label maximum. |
Source: Jastreboff et al., NEJM 2022 (SURMOUNT-1), primary treatment-regimen estimand, which includes outcomes regardless of treatment discontinuation. These group averages do not determine an individual’s dose.
Steady state
Tirzepatide has a 5-day half-life. With weekly dosing, blood levels build up over about 4 weeks before stabilizing at roughly 1.6× a single dose. That is why each phase lasts at least 4 weeks, allowing the body time to adjust before a new dose's effect can be judged.
Tirzepatide Supplies Needed
These theoretical mass-only minima assume four weeks each at 2.5, 5, 7.5, 10, 12.5, and 15 mg, using nominal 40 mg vials and 2.0 mL per vial. This fixed ladder is only a calculation example. It does not establish research-product equivalence, a treatment plan, or usable life; actual counts depend on validated discard dates and losses.
Recommended Supply
Choose your region
Use discount code SAVE10 at Peptira checkout. See why we love Peptira.
Tirzepatide
Pharmacy Grade Tirzepatide
At-Home Blood Test
Research Supplies
Disclosure: supply links may earn PDP a commission at no cost to you.
Tirzepatide Vials (40 mg, reconstituted to 20 mg/mL)
A 40 mg vial contains eight 5 mg amounts, four 10 mg amounts, or two complete 15 mg amounts before losses. This is mass arithmetic, not a usable-life claim.
| Calculation period | Arithmetic note |
|---|---|
4 weeks (Phase 1, 2.5 mg), 8 weeks (through 5 mg) 1 x 40 mg vial (mass-only minimum) | 4 weeks (Phase 1, 2.5 mg): 4 × 2.5 mg = 10 mg total; one 40 mg vial is the mass-only minimum.; 8 weeks (through 5 mg): 30 mg total. One 40 mg vial is the mass-only minimum, not permission to use one opened vial for 8 weeks. |
12 weeks (through 7.5 mg) 2 x 40 mg vials (mass-only minimum) | 60 mg total; two 40 mg vials are the mass-only minimum. |
16 weeks (through 10 mg) 3 x 40 mg vials (mass-only minimum) | 100 mg total; three 40 mg vials are the mass-only minimum. |
24 weeks (full ladder to 15 mg) 6 x 40 mg vials (mass-only minimum) | 210 mg total; six 40 mg vials are the mass-only minimum. Different dose timing changes this total. |
4 weeks (Phase 1, 2.5 mg), 8 weeks (through 5 mg)
1 x 40 mg vial (mass-only minimum)
4 weeks (Phase 1, 2.5 mg): 4 × 2.5 mg = 10 mg total; one 40 mg vial is the mass-only minimum.; 8 weeks (through 5 mg): 30 mg total. One 40 mg vial is the mass-only minimum, not permission to use one opened vial for 8 weeks.
12 weeks (through 7.5 mg)
2 x 40 mg vials (mass-only minimum)
60 mg total; two 40 mg vials are the mass-only minimum.
16 weeks (through 10 mg)
3 x 40 mg vials (mass-only minimum)
100 mg total; three 40 mg vials are the mass-only minimum.
24 weeks (full ladder to 15 mg)
6 x 40 mg vials (mass-only minimum)
210 mg total; six 40 mg vials are the mass-only minimum. Different dose timing changes this total.
Insulin Syringes (U-100)
One syringe per weekly injection. Use 0.5 mL syringes for ≤50 unit draws and 1 mL syringes for higher doses.
| Calculation period | Arithmetic note |
|---|---|
4 weeks 4 syringes | 1 per weekly injection. |
12 weeks 12 syringes | 1 box of 100 covers a full ladder. |
24 weeks 24 syringes | Add a few extras for dropped or damaged syringes. |
4 weeks
4 syringes
1 per weekly injection.
12 weeks
12 syringes
1 box of 100 covers a full ladder.
24 weeks
24 syringes
Add a few extras for dropped or damaged syringes.
Bacteriostatic Water
Volume arithmetic assumes 2.0 mL per nominal 40 mg vial. Bottle count also depends on the manufacturer’s post-opening discard period and any additional vials needed after discard or loss.
| Calculation period | Arithmetic note |
|---|---|
4 weeks 2 mL total | One mass-only vial minimum × 2 mL. This does not establish how long an opened water bottle is usable. |
24 weeks 12 mL total | Six mass-only vial minima × 2 mL = 12 mL. Bottle count must also account for post-opening discard dates. |
4 weeks
2 mL total
One mass-only vial minimum × 2 mL. This does not establish how long an opened water bottle is usable.
24 weeks
12 mL total
Six mass-only vial minima × 2 mL = 12 mL. Bottle count must also account for post-opening discard dates.
Vial counts are theoretical mass-only minima. Determine product-specific discard dates and unused remnants separately; no generic research-vial beyond-use period is established here. Water-bottle counts also depend on post-opening discard instructions.
Companion Supplies & Routine Support
Tirzepatide Reconstitution Calculator
Powered by PepPal
Tirzepatide Reconstitution Calculator
Start with the protocol example, then customize every field.
Loaded reference
PDP research-vial baseline
This calculator does not apply to Mounjaro or Zepbound pens or other premixed products.
Your draw
12.5units
0.125 mL on a U-100 insulin syringe
- Concentration
- 20 mg/mL
- Target in mg
- 2.5 mg
- Math-only doses per vial
- 16
One free emailed save per person, checked by PepPal.
By submitting your email, you’re signing up for Peptide Dosing Protocols and PepPal updates, supplier deals, and promotional emails. Unsubscribe anytime. Privacy Policy.
Educational calculation tool only. The loaded amount is a reference from this page, not a personal dose recommendation. Confirm the vial label, route, syringe type, and actual liquid added before relying on a result.
Tirzepatide Reconstitution Guide
These nominal research-vial calculations use mass divided by final solution volume. They are separate from approved product instructions and do not validate a preparation method, diluent, stability, or suitability for human use.
Tirzepatide reconstitution by vial size (units assume U-100 insulin syringes)
Vial
5 mg
Example final volume
1.0 mL
Concentration
5 mg/mL
2.5 mg
0.50 mL / 50 u
5 mg
1.00 mL / 100 u
7.5 mg
Exceeds total vial content
10 mg
Exceeds total vial content
15 mg
Exceeds total vial content
Vial
10 mg
Example final volume
1.0 mL
Concentration
10 mg/mL
2.5 mg
0.25 mL / 25 u
5 mg
0.50 mL / 50 u
7.5 mg
0.75 mL / 75 u
10 mg
1.00 mL / 100 u
15 mg
Exceeds total vial content
Vial
10 mg
Example final volume
2.0 mL
Concentration
5 mg/mL
2.5 mg
0.50 mL / 50 u
5 mg
1.00 mL / 100 u
7.5 mg
1.50 mL / 150 u; exceeds 1 mL capacity
10 mg
2.00 mL / 200 u; exceeds 1 mL capacity
15 mg
Exceeds total vial content
Vial
15 mg
Example final volume
1.5 mL
Concentration
10 mg/mL
2.5 mg
0.25 mL / 25 u
5 mg
0.50 mL / 50 u
7.5 mg
0.75 mL / 75 u
10 mg
1.00 mL / 100 u
15 mg
1.50 mL / 150 u; exceeds 1 mL capacity
Vial
40 mg
Example final volume
2.0 mL
Concentration
20 mg/mL
2.5 mg
0.125 mL / 12.5 u
5 mg
0.25 mL / 25 u
7.5 mg
0.375 mL / 37.5 u
10 mg
0.50 mL / 50 u
15 mg
0.75 mL / 75 u
Vial
40 mg
Example final volume
3.0 mL
Concentration
13.33 mg/mL
2.5 mg
0.188 mL / 18.8 u
5 mg
0.375 mL / 37.5 u
7.5 mg
0.563 mL / 56.3 u
10 mg
0.75 mL / 75 u
15 mg
1.125 mL / 112.5 u; exceeds 1 mL capacity
Vial
60 mg
Example final volume
3.0 mL
Concentration
20 mg/mL
2.5 mg
0.125 mL / 12.5 u
5 mg
0.25 mL / 25 u
7.5 mg
0.375 mL / 37.5 u
10 mg
0.50 mL / 50 u
15 mg
0.75 mL / 75 u
| Vial | Example final volume | Concentration | 2.5 mg | 5 mg | 7.5 mg | 10 mg | 15 mg |
|---|---|---|---|---|---|---|---|
| 5 mg | 1.0 mL | 5 mg/mL | 0.50 mL / 50 u | 1.00 mL / 100 u | Exceeds total vial content | Exceeds total vial content | Exceeds total vial content |
| 10 mg | 1.0 mL | 10 mg/mL | 0.25 mL / 25 u | 0.50 mL / 50 u | 0.75 mL / 75 u | 1.00 mL / 100 u | Exceeds total vial content |
| 10 mg | 2.0 mL | 5 mg/mL | 0.50 mL / 50 u | 1.00 mL / 100 u | 1.50 mL / 150 u; exceeds 1 mL capacity | 2.00 mL / 200 u; exceeds 1 mL capacity | Exceeds total vial content |
| 15 mg | 1.5 mL | 10 mg/mL | 0.25 mL / 25 u | 0.50 mL / 50 u | 0.75 mL / 75 u | 1.00 mL / 100 u | 1.50 mL / 150 u; exceeds 1 mL capacity |
| 40 mg | 2.0 mL | 20 mg/mL | 0.125 mL / 12.5 u | 0.25 mL / 25 u | 0.375 mL / 37.5 u | 0.50 mL / 50 u | 0.75 mL / 75 u |
| 40 mg | 3.0 mL | 13.33 mg/mL | 0.188 mL / 18.8 u | 0.375 mL / 37.5 u | 0.563 mL / 56.3 u | 0.75 mL / 75 u | 1.125 mL / 112.5 u; exceeds 1 mL capacity |
| 60 mg | 3.0 mL | 20 mg/mL | 0.125 mL / 12.5 u | 0.25 mL / 25 u | 0.375 mL / 37.5 u | 0.50 mL / 50 u | 0.75 mL / 75 u |
U-100 units measure volume: 100 units = 1 mL. Vial capacity is product-specific. Amounts exceeding vial content or syringe capacity cannot be treated as a single draw; this table does not specify administration or splitting.
- 01
Identify the product
Approved finished products, compounded preparations, and research powders have different instructions. A nominal vial label does not establish equivalence.
- 02
Record mass and final volume
For the example, use 40 mg and a final volume of 2.0 mL. These are arithmetic assumptions, not mixing instructions.
- 03
Calculate concentration
40 mg divided by 2.0 mL equals 20 mg/mL.
- 04
Convert a reference amount
At 20 mg/mL, 5 mg equals 0.25 mL. On a U-100 scale, 0.25 mL equals 25 units.
- 05
Check capacity and storage separately
Vial content, syringe capacity, sterility, and a product-specific discard date cannot be inferred from this calculation.
Need a different ratio?
Use the PepPal reconstitution calculator for any vial-and-water pairing. Enter vial mg, water volume, and target dose to get exact syringe units.
Tirzepatide Dosage Chart
This chart mirrors the adult Zepbound example in the dosing table. It shows the earliest timing if each increase is needed and tolerated, including the 12.5 mg step at weeks 17–20. The maximum is not a required target.
How Tirzepatide Works
Tirzepatide is a 39-amino-acid synthetic peptide with a fatty-acid attachment. The fatty acid is what lets it bind to blood proteins and stay in circulation long enough for once-weekly dosing — its half-life is roughly 5 days. Once in circulation, it activates two receptors that the gut normally talks to after a meal: GIP and GLP-1.
GIP pathway
Tirzepatide activates GIP (glucose-dependent insulinotropic polypeptide) receptors at full strength, comparable to natural GIP. This helps the pancreas release insulin in response to food, improves how the body processes fat, and sends appetite-reducing signals to brain regions that GLP-1-only drugs do not reach.
GLP-1 pathway
Tirzepatide activates GLP-1 (glucagon-like peptide-1) receptors at about one-fifth the potency of natural GLP-1. This slows gastric emptying (so meals feel filling for longer), helps the pancreas tune insulin release, and suppresses appetite through brain signaling.
Why the combination matters
Adding GIP activation is what separates tirzepatide from semaglutide. In the head-to-head SURMOUNT-5 trial (NEJM, 2025), tirzepatide produced −20.2% body weight loss vs −13.7% for semaglutide at 72 weeks, with similar side-effect profiles. The dual approach also improved insulin sensitivity beyond what GLP-1 monotherapy delivered in SURPASS-2.
Who Tirzepatide Is For and Who Should Avoid It
Tirzepatide indications depend on the product and age group. A contraindication means the medicine should not be used; it is not waived by clinician supervision.
Approved patient groups
FDA-approved indications (current labels, October 2026)
Brand
Mounjaro
Indication
Type 2 diabetes
Population
Adults and children age 10 or older, as an adjunct to diet and exercise; pediatric maximum 10 mg weekly.
Brand
Mounjaro
Indication
Reduction of major cardiovascular events
Population
Adults with type 2 diabetes at high cardiovascular risk; follow the current Mounjaro label.
Brand
Zepbound
Indication
Chronic weight management
Population
Adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related condition.
Brand
Zepbound
Indication
Obstructive sleep apnea
Population
Adults with moderate-to-severe OSA who also have obesity.
| Brand | Indication | Population |
|---|---|---|
| Mounjaro | Type 2 diabetes | Adults and children age 10 or older, as an adjunct to diet and exercise; pediatric maximum 10 mg weekly. |
| Mounjaro | Reduction of major cardiovascular events | Adults with type 2 diabetes at high cardiovascular risk; follow the current Mounjaro label. |
| Zepbound | Chronic weight management | Adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related condition. |
| Zepbound | Obstructive sleep apnea | Adults with moderate-to-severe OSA who also have obesity. |
Who should not use tirzepatide
Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
Boxed warning. Rodent studies showed thyroid C-cell tumors. Tirzepatide is contraindicated in this group.
History of pancreatitis
Pancreatitis has been reported. Patients with prior episodes should avoid tirzepatide unless a clinician decides the benefit clearly outweighs the risk.
Pregnancy
Tirzepatide may cause fetal harm. Discuss pregnancy plans and stopping treatment with the prescriber. Zepbound should be discontinued when pregnancy is recognized; do not transfer semaglutide’s two-month instruction to tirzepatide.
Severe gastrointestinal disease (gastroparesis, severe IBD)
Tirzepatide slows gastric emptying. Patients with pre-existing severe motility issues may experience worse symptoms.
Type 1 diabetes
Tirzepatide is not a substitute for insulin. It is not approved for type 1 diabetes or for diabetic ketoacidosis.
Children and adolescents
Mounjaro is approved for type 2 diabetes from age 10; the maximum for ages 10–17 is 10 mg weekly. Zepbound labeling is for adults. Do not apply the 15 mg adult maximum to pediatric Mounjaro use.
People using oral contraceptives
Slowed gastric emptying can reduce oral contraceptive absorption when starting tirzepatide. Backup contraception is recommended for the first 4 weeks of dosing and after every dose increase.
Tirzepatide Side Effects & Safety
Most tirzepatide side effects are digestive: nausea, diarrhea, vomiting, reduced appetite, and indigestion. They are usually worst during the weeks when the dose goes up and improve once the body adjusts. Below are the rates reported across the SURPASS and SURMOUNT trial programs.
Common side effects (SURPASS meta-analysis and SURMOUNT-1 reporting)
Side effect
Nausea
Approx. rate on tirzepatide
17–22%
Pattern
Worst during dose escalation; improves at stable dose.
Side effect
Diarrhea
Approx. rate on tirzepatide
13–16%
Pattern
Mild to moderate; rarely leads to discontinuation.
Side effect
Vomiting
Approx. rate on tirzepatide
6–10%
Pattern
More common at 10 mg and 15 mg.
Side effect
Decreased appetite
Approx. rate on tirzepatide
7–9%
Pattern
Often reported as a desired effect for weight loss.
Side effect
Indigestion
Approx. rate on tirzepatide
~7%
Pattern
Often paired with slower digestion.
Side effect
Injection-site reactions
Approx. rate on tirzepatide
3–7%
Pattern
Redness, mild itching, or local irritation.
Side effect
Resting heart rate increase
Approx. rate on tirzepatide
+2–4 bpm
Pattern
Modest. Larger increases are uncommon.
| Side effect | Approx. rate on tirzepatide | Pattern |
|---|---|---|
| Nausea | 17–22% | Worst during dose escalation; improves at stable dose. |
| Diarrhea | 13–16% | Mild to moderate; rarely leads to discontinuation. |
| Vomiting | 6–10% | More common at 10 mg and 15 mg. |
| Decreased appetite | 7–9% | Often reported as a desired effect for weight loss. |
| Indigestion | ~7% | Often paired with slower digestion. |
| Injection-site reactions | 3–7% | Redness, mild itching, or local irritation. |
| Resting heart rate increase | +2–4 bpm | Modest. Larger increases are uncommon. |
Source: meta-analyses across SURPASS; SURMOUNT-1 (NEJM 2022). Rates differ by trial and dose.
Side effects by dose
A meta-analysis of 10 trials (6,836 participants) found total GI event rates of 39% at 5 mg, 46% at 10 mg, and 49% at 15 mg. Discontinuation due to side effects ran from about 5% at 5 mg to about 10% at 15 mg.
Serious risks and warnings
Boxed warning: thyroid C-cell tumors
Rodent studies showed dose-dependent C-cell tumors. The clinical relevance in humans is uncertain, but use is contraindicated in patients with MTC history or MEN 2.
Pancreatitis
Acute pancreatitis has been reported. Stop tirzepatide if pancreatitis is suspected (severe abdominal pain that radiates to the back).
Gallbladder disease
Cholelithiasis and cholecystitis have been reported, consistent with rapid weight loss generally.
Hypoglycemia
Tirzepatide alone rarely causes low blood sugar, but the risk rises sharply when combined with insulin or sulfonylureas. Dose adjustments to those drugs are usually needed.
Acute kidney injury
Severe nausea and vomiting can lead to dehydration and AKI. Stay hydrated, especially during dose escalation. For practical support, review hydration, smaller meals, and GLP-1 supplement basics.
Hypersensitivity
Anaphylaxis and angioedema have been reported. Discontinue if a serious allergic reaction occurs.
Tirzepatide Timeline & What to Monitor
Tirzepatide builds up gradually. Because the half-life is about 5 days, with weekly dosing blood levels rise for the first 4 weeks before stabilizing. That is also why each dose step lasts at least 4 weeks; anything sooner evaluates the new dose before it has fully accumulated.
What people typically notice across the ladder
Timeframe
Week 1–2 (2.5 mg)
What is reported
Mild appetite reduction; some early nausea.
What the trials measured
Baseline labs; no efficacy endpoint expected.
Timeframe
Week 4–8 (2.5 → 5 mg)
What is reported
Steadier appetite suppression; first weight changes.
What the trials measured
Early HbA1c shift in T2D; modest weight loss in obesity arms.
Timeframe
Week 12–16 (5 → 10 mg)
What is reported
Most pronounced appetite and weight changes.
What the trials measured
Roughly 10–15% weight loss in obesity arms by week 24.
Timeframe
Week 24+ (10 → 15 mg)
What is reported
Weight loss plateaus or continues slowly.
What the trials measured
−19.5% (10 mg) and −20.9% (15 mg) at 72 weeks (SURMOUNT-1).
| Timeframe | What is reported | What the trials measured |
|---|---|---|
| Week 1–2 (2.5 mg) | Mild appetite reduction; some early nausea. | Baseline labs; no efficacy endpoint expected. |
| Week 4–8 (2.5 → 5 mg) | Steadier appetite suppression; first weight changes. | Early HbA1c shift in T2D; modest weight loss in obesity arms. |
| Week 12–16 (5 → 10 mg) | Most pronounced appetite and weight changes. | Roughly 10–15% weight loss in obesity arms by week 24. |
| Week 24+ (10 → 15 mg) | Weight loss plateaus or continues slowly. | −19.5% (10 mg) and −20.9% (15 mg) at 72 weeks (SURMOUNT-1). |
SURMOUNT-1 values use the primary treatment-regimen estimand. These population averages do not determine an individual’s dose or result.
What is reasonable to monitor
Weight and waist circumference
Trial endpoints. Weekly weight and monthly waist measurements are simple at-home markers.
HbA1c (for T2D users)
Standard glycemic marker. SURPASS-2 showed up to −2.30% from baseline at 40 weeks.
Blood pressure
Tirzepatide modestly lowers systolic BP (~5 mmHg in SUMMIT). Patients on antihypertensives should track BP during escalation.
Resting heart rate
A 2–4 bpm rise is common. Larger sustained increases warrant a clinician check.
Symptoms of pancreatitis or gallbladder problems
Severe abdominal pain, back pain, fever, jaundice — stop and seek medical care.
Hydration and kidney symptoms
Especially during heavy nausea or vomiting.
Tirzepatide Clinical Evidence Context
Tirzepatide has one of the largest clinical trial programs of any incretin drug. The SURPASS program (type 2 diabetes) enrolled more than 19,000 participants across 10 trials. The SURMOUNT program (obesity) added thousands more, including the head-to-head SURMOUNT-5 trial against semaglutide. The summary below pulls the headline numbers from each pivotal study.
Pivotal Phase 3 trials
Trial
SURMOUNT-1 (NEJM 2022)
Population
2,539 adults, obesity, no diabetes; 72 weeks
Headline result
Primary treatment-regimen estimand: −20.9% at 15 mg, −19.5% at 10 mg, and −15.0% at 5 mg.
Trial
SURMOUNT-5 (NEJM 2025)
Population
751 adults, obesity, no diabetes; head-to-head vs semaglutide; 72 weeks
Headline result
Tirzepatide −20.2% vs semaglutide −13.7% (P<0.001).
Trial
SURPASS-2 (NEJM 2021)
Population
1,879 adults with T2D vs semaglutide 1 mg; 40 weeks
Headline result
All tirzepatide doses superior. HbA1c up to −2.30%; up to 92% reached HbA1c <7%.
Trial
SURPASS-1 (Lancet 2021)
Population
478 adults with T2D, monotherapy vs placebo; 40 weeks
Headline result
Up to 52% achieved HbA1c <5.7% (non-diabetic range).
Trial
SURPASS-5 (JAMA 2022)
Population
475 adults with T2D + insulin glargine; 40 weeks
Headline result
HbA1c −2.11% to −2.34%; weight loss 5.4–8.8 kg.
Trial
SUMMIT (NEJM 2024)
Population
731 patients with HFpEF + obesity; 104 weeks median
Headline result
38% reduction in CV death or worsening heart failure (HR 0.62).
Trial
SURMOUNT-OSA (NEJM 2024)
Population
469 adults with moderate-to-severe OSA + obesity; 52 weeks
Headline result
AHI reduced by 25.3–29.3 events/hour; weight loss ~45–50 lbs.
| Trial | Population | Headline result |
|---|---|---|
| SURMOUNT-1 (NEJM 2022) | 2,539 adults, obesity, no diabetes; 72 weeks | Primary treatment-regimen estimand: −20.9% at 15 mg, −19.5% at 10 mg, and −15.0% at 5 mg. |
| SURMOUNT-5 (NEJM 2025) | 751 adults, obesity, no diabetes; head-to-head vs semaglutide; 72 weeks | Tirzepatide −20.2% vs semaglutide −13.7% (P<0.001). |
| SURPASS-2 (NEJM 2021) | 1,879 adults with T2D vs semaglutide 1 mg; 40 weeks | All tirzepatide doses superior. HbA1c up to −2.30%; up to 92% reached HbA1c <7%. |
| SURPASS-1 (Lancet 2021) | 478 adults with T2D, monotherapy vs placebo; 40 weeks | Up to 52% achieved HbA1c <5.7% (non-diabetic range). |
| SURPASS-5 (JAMA 2022) | 475 adults with T2D + insulin glargine; 40 weeks | HbA1c −2.11% to −2.34%; weight loss 5.4–8.8 kg. |
| SUMMIT (NEJM 2024) | 731 patients with HFpEF + obesity; 104 weeks median | 38% reduction in CV death or worsening heart failure (HR 0.62). |
| SURMOUNT-OSA (NEJM 2024) | 469 adults with moderate-to-severe OSA + obesity; 52 weeks | AHI reduced by 25.3–29.3 events/hour; weight loss ~45–50 lbs. |
The current Mounjaro label includes major cardiovascular-event risk reduction in high-risk adults with type 2 diabetes; see its indication and clinical-study sections for product-specific evidence.
Strongest weight-loss evidence
SURMOUNT-1 and the head-to-head SURMOUNT-5 are the gold-standard data points for tirzepatide weight loss. Both are large, multicenter, randomized, placebo- or semaglutide-controlled.
Strongest glycemic evidence
SURPASS-2 is the most cited head-to-head against semaglutide for HbA1c reduction in type 2 diabetes.
Cardiovascular evidence
SUMMIT studied cardiovascular death or worsening heart failure in adults with HFpEF and obesity. Separately, the current Mounjaro label includes major cardiovascular-event risk reduction in adults with type 2 diabetes at high cardiovascular risk. These are different populations and endpoints.
Evidence gaps
Long-term (5+ year) outcomes data is still being collected. Post-discontinuation weight regain has been observed in trial extensions; tirzepatide is treated as a chronic therapy.
Tirzepatide Storage & Handling
Storage instructions are product-specific
Product
Mounjaro or Zepbound finished product
Use these instructions
The exact presentation’s current carton, Instructions for Use, and prescribing information
Important limit
Room-temperature and after-opening limits differ by product; do not apply one pen’s rule to another product.
Product
Compounded preparation
Use these instructions
The dispensing pharmacy’s product-specific storage and beyond-use date
Important limit
The brand label does not validate a compounded preparation’s stability.
Product
Research powder or solution
Use these instructions
Validated product-specific stability and handling data
Important limit
No generic 28-day, shipping, refrigerated, or frozen-storage allowance is established here.
Product
Bacteriostatic water
Use these instructions
Manufacturer’s label and post-opening discard instructions
Important limit
The water bottle’s discard date is separate from the peptide solution’s date.
| Product | Use these instructions | Important limit |
|---|---|---|
| Mounjaro or Zepbound finished product | The exact presentation’s current carton, Instructions for Use, and prescribing information | Room-temperature and after-opening limits differ by product; do not apply one pen’s rule to another product. |
| Compounded preparation | The dispensing pharmacy’s product-specific storage and beyond-use date | The brand label does not validate a compounded preparation’s stability. |
| Research powder or solution | Validated product-specific stability and handling data | No generic 28-day, shipping, refrigerated, or frozen-storage allowance is established here. |
| Bacteriostatic water | Manufacturer’s label and post-opening discard instructions | The water bottle’s discard date is separate from the peptide solution’s date. |
Mass arithmetic, a preservative, and clear appearance do not establish sterility or stability.
Tirzepatide Protocol Mistakes & Troubleshooting
- 01
Missed a weekly dose
The prescribing information states that when less than 4 days (96 hours) have passed, a missed dose may be taken and the regular weekly schedule resumed. After more than 4 days, the missed dose is skipped and dosing returns on the regular day without doubling up.
- 02
Cloudy, particulate, or off-color vial
Reconstituted tirzepatide should be clear, colorless to slightly yellow, and free of visible particles. If the solution is cloudy or has floaters, do not inject. Discard and reconstitute a new vial.
- 03
Wrong BAC water volume
If you added more water than planned (e.g., 3 mL into a 40 mg vial instead of 2 mL), recalculate the new concentration (in this case 13.33 mg/mL) and adjust the syringe units. Use the PepPal calculator. That changes the nominal concentration; it does not establish stability or suitability for use.
- 04
Severe nausea on a new dose
Trial protocols allowed the current dose to be held for an additional 4 weeks before escalation was attempted again. Hydration, smaller meals, and avoiding fatty or spicy foods are commonly reported supportive measures.
- 05
Injection-site lump or redness
Label guidance describes rotating sites between the abdomen, thigh, and upper arm and avoiding the same spot in consecutive weeks. Persistent or worsening reactions warrant a clinician check.
- 06
Vial left at room temperature
Do not infer usability from a generic time limit. Use the exact product’s temperature-excursion instructions or ask its dispensing pharmacist or manufacturer. Research powders and solutions have no validated room-temperature allowance on this page.
- 07
Confused about Mounjaro vs Zepbound dose
Check the brand, indication, and age group. Zepbound weight-reduction maintenance is 5/10/15 mg; OSA maintenance is 10/15 mg. Mounjaro dose increases depend on glycemic need, with adult maximum 15 mg and pediatric maximum 10 mg weekly.
- 08
Severe abdominal pain, jaundice, or unrelenting vomiting
Stop the next dose and seek qualified medical care. These symptoms can signal pancreatitis, gallbladder disease, or dehydration-driven kidney injury.
Tirzepatide Regulatory Status
Current U.S. labels reviewed October 14, 2026 distinguish two tirzepatide brands. Mounjaro is indicated for type 2 diabetes from age 10 and major cardiovascular-event risk reduction in high-risk adults with type 2 diabetes. Zepbound is indicated for adult weight reduction and long-term maintenance, and moderate-to-severe OSA in adults with obesity. Approval applies to those finished products, not research powders.
Branded supply
Mounjaro and Zepbound are FDA-approved finished drug products from Eli Lilly. Available presentations and their handling instructions are listed in the current product-specific prescribing information.
Compounded supply
Compounded tirzepatide was widely available during the FDA-recognized shortage that ended in late 2024. Outside an active shortage, large-scale compounding is restricted; access depends on state pharmacy rules and 503A/503B compounding pathways. Quality and concentration vary by compounder.
Research-grade vials
Lyophilized research-grade tirzepatide is sold by laboratory chemical suppliers in 5/10/15/40/60 mg vials, labeled for research use only and not for human consumption. This is a separate, non-FDA supply chain.
Oral tirzepatide
There is no FDA-approved oral tirzepatide as of June 2026. "Tirzepatide pills" or "tirzepatide tablets" sold online are not FDA-approved formulations and lack established bioavailability data.
International status
Tirzepatide is approved in the EU, UK, Japan, and other markets under the Mounjaro and Zepbound names. The UK BNF lists it for both T2D and weight management.
Tirzepatide vs Semaglutide vs Retatrutide
Three incretin-class compounds dominate the conversation: tirzepatide (dual GIP/GLP-1), semaglutide (GLP-1 only, sold as Ozempic and Wegovy), and retatrutide (triple agonist GLP-1 + GIP + glucagon, still investigational). The table below puts them side by side on the points that matter most to dosing decisions.
Side-by-side compound comparison
Receptor targets
Tirzepatide
GLP-1 + GIP (dual)
Semaglutide
GLP-1 only
Retatrutide
GLP-1 + GIP + Glucagon (triple)
Half-life
Tirzepatide
~5 days
Semaglutide
~7 days
Retatrutide
~6 days
Dosing frequency
Tirzepatide
Once weekly
Semaglutide
Once weekly
Retatrutide
Once weekly
Dose context
Tirzepatide
15 mg/week adult maximum; pediatric Mounjaro maximum 10 mg
Semaglutide
Optional Wegovy 7.2 mg/week only for adult weight reduction under label conditions
Retatrutide
12 mg/week highest target in initial TRIUMPH trials
Selected trial results; separate studies
Tirzepatide
−20.9% (SURMOUNT-1, 72 wk; treatment-regimen estimand)
Semaglutide
−14.9% (STEP-1, 68 wk; treatment-policy estimand)
Retatrutide
−24.2% (Phase 2, 48 wk)
FDA status (June 2026)
Tirzepatide
Approved (T2D, obesity, OSA)
Semaglutide
Approved (T2D, obesity, CV risk)
Retatrutide
Investigational — Phase 3
Head-to-head
Tirzepatide
−20.2% vs semaglutide −13.7% (SURMOUNT-5)
Semaglutide
—
Retatrutide
Not yet head-to-head vs tirzepatide
HFpEF benefit
Tirzepatide
Yes (SUMMIT, HR 0.62)
Semaglutide
Yes (STEP-HFpEF)
Retatrutide
Not yet studied
Unique advantage
Tirzepatide
Best-in-class FDA-approved efficacy; 3 indications
Semaglutide
Longest track record; CV outcomes data
Retatrutide
Highest weight loss in early data
| Tirzepatide | Semaglutide | Retatrutide | |
|---|---|---|---|
| Receptor targets | GLP-1 + GIP (dual) | GLP-1 only | GLP-1 + GIP + Glucagon (triple) |
| Half-life | ~5 days | ~7 days | ~6 days |
| Dosing frequency | Once weekly | Once weekly | Once weekly |
| Dose context | 15 mg/week adult maximum; pediatric Mounjaro maximum 10 mg | Optional Wegovy 7.2 mg/week only for adult weight reduction under label conditions | 12 mg/week highest target in initial TRIUMPH trials |
| Selected trial results; separate studies | −20.9% (SURMOUNT-1, 72 wk; treatment-regimen estimand) | −14.9% (STEP-1, 68 wk; treatment-policy estimand) | −24.2% (Phase 2, 48 wk) |
| FDA status (June 2026) | Approved (T2D, obesity, OSA) | Approved (T2D, obesity, CV risk) | Investigational — Phase 3 |
| Head-to-head | −20.2% vs semaglutide −13.7% (SURMOUNT-5) | — | Not yet head-to-head vs tirzepatide |
| HFpEF benefit | Yes (SUMMIT, HR 0.62) | Yes (STEP-HFpEF) | Not yet studied |
| Unique advantage | Best-in-class FDA-approved efficacy; 3 indications | Longest track record; CV outcomes data | Highest weight loss in early data |
These compounds are not interchangeable. Cross-trial results differ in population, duration, and estimand; they do not establish a ranking. Research-vial calculations do not establish equivalence to approved or trial products.
For an oral, non-incretin alternative, see the tesofensine protocol. For dedicated guides, see the semaglutide protocol and retatrutide protocol.
Tirzepatide Blood Tests & Monitoring
Tirzepatide is an approved GIP/GLP-1 receptor agonist used in diabetes and weight-management contexts. Monitoring focuses on glucose control, kidney context, lipids, GI symptoms, gallbladder/pancreas symptoms, and thyroid-history cautions.
Blood test markers to discuss with a clinician
Marker
A1c
Why it matters
Shows longer-term glucose control and helps track metabolic response over time.
Timing
Baseline
Marker
Fasting glucose
Why it matters
Gives a current glucose snapshot, especially when appetite and diabetes medication needs change.
Timing
Follow-up
Marker
Comprehensive metabolic panel (CMP)
Why it matters
Reviews kidney function, liver enzymes, electrolytes, and glucose, which matter with GI symptoms or dehydration.
Timing
Baseline
Marker
Lipid panel
Why it matters
Tracks cardiometabolic changes during weight-loss or diabetes-management phases.
Timing
Follow-up
Marker
Blood pressure and resting heart rate
Why it matters
Adds cardiovascular context during weight loss, medication changes, and hydration shifts.
Timing
Optional
| Marker | Why it matters | Timing |
|---|---|---|
| A1c | Shows longer-term glucose control and helps track metabolic response over time. | Baseline |
| Fasting glucose | Gives a current glucose snapshot, especially when appetite and diabetes medication needs change. | Follow-up |
| Comprehensive metabolic panel (CMP) | Reviews kidney function, liver enzymes, electrolytes, and glucose, which matter with GI symptoms or dehydration. | Baseline |
| Lipid panel | Tracks cardiometabolic changes during weight-loss or diabetes-management phases. | Follow-up |
| Blood pressure and resting heart rate | Adds cardiovascular context during weight loss, medication changes, and hydration shifts. | Optional |
Monitoring guidance is label-informed for tirzepatide and supported by incretin-class clinical monitoring considerations.
At-home blood test option
Easy at home option to monitor core metrics during research cycles.
Beyond Whoosh
Pharmacy Grade Tirzepatide
Prescription-grade peptide care through Beyond Whoosh. Whoosh prescribes after a clinician reviews your eligibility.
Partner link: PDP may earn a commission at no cost to you.
Simple timing framework
Baseline
Discuss baseline labs before starting or changing dose, especially with diabetes, kidney disease, pancreatitis history, gallbladder history, thyroid cancer history, or major calorie restriction.
Follow-up
Repeat glucose and CMP-related markers after 4-12 weeks or sooner if vomiting, dehydration, or glucose symptoms occur.
Longer term
For ongoing use, review metabolic and kidney trends every 3-6 months with a clinician.
How to interpret the labs
- Diabetes medications may need clinician review if glucose drops with reduced intake.
- Severe abdominal pain, gallbladder symptoms, and persistent vomiting require symptom-based review.
- Personal or family history of medullary thyroid carcinoma or MEN2 is an important label-based caution.
Do not wait for routine labs
Severe abdominal pain, persistent vomiting, signs of dehydration, fainting, allergic symptoms, or severe low-glucose symptoms need medical review. A neck mass, trouble swallowing, or persistent hoarseness should be discussed with a clinician.
FAQ
Q1: What is the starting dose of tirzepatide?
For adult Zepbound use, the label starts at 2.5 mg once weekly for 4 weeks, then 5 mg. Later 2.5 mg increases are optional after at least 4 weeks at the current dose, based on response and tolerability. The current Mounjaro label starts at 2.5 mg weekly and links increases to the need for additional glycemic control. Product, indication, and age group matter; the adult Zepbound table is not a universal tirzepatide schedule.
Q2: What is the highest dose of tirzepatide / Zepbound?
The adult maximum for Mounjaro and Zepbound is 15 mg once weekly. For Mounjaro in children ages 10–17 with type 2 diabetes, the maximum is 10 mg weekly. Zepbound maintenance is 5, 10, or 15 mg for weight reduction and 10 or 15 mg for OSA. These are product-label limits, not required targets or instructions for research powders.
Q3: What is tirzepatide's half-life?
Tirzepatide's half-life is approximately 5 days (about 120 hours). This is what supports once-weekly dosing. With weekly injections, blood levels build up over about 4 weeks before reaching steady state at roughly 1.6× a single dose. That is why each ladder step lasts at least 4 weeks — the body needs that time to fully adjust.
Q4: How do you convert tirzepatide mg to insulin units?
U-100 markings measure volume: 1 mL = 100 units. For a nominal arithmetic example, 40 mg in a final 2.0 mL gives 20 mg/mL. This does not establish preparation instructions or human use. At that concentration: 2.5 mg = 12.5 units, 5 mg = 25 units, 7.5 mg = 37.5 units, 10 mg = 50 units, 12.5 mg = 62.5 units, 15 mg = 75 units. For any other vial-and-water pairing, use the PepPal calculator.
Q5: How much weight can you lose on tirzepatide?
In SURMOUNT-1 (NEJM 2022, 2,539 adults with obesity), the primary treatment-regimen estimand showed average weight changes of −20.9% at 15 mg, −19.5% at 10 mg, and −15.0% at 5 mg over 72 weeks. In the head-to-head SURMOUNT-5 trial (NEJM 2025), tirzepatide produced −20.2% weight loss vs −13.7% for semaglutide. These are population averages over 72 weeks, not promises for any individual.
Q6: How do you reconstitute tirzepatide?
This page gives nominal research-vial calculations, not validated preparation instructions. For example, 40 mg in a final 2.0 mL equals 20 mg/mL. Approved products and compounded preparations follow their own instructions. The calculation does not establish identity, sterility, stability, or equivalence to Mounjaro or Zepbound. Use the PepPal calculator for arithmetic only.
Q7: Is tirzepatide FDA-approved?
Yes, as specific finished products. The current Mounjaro label covers type 2 diabetes from age 10 and major cardiovascular-event risk reduction in high-risk adults with type 2 diabetes. Zepbound covers adult weight reduction and long-term maintenance, and moderate-to-severe OSA in adults with obesity. Research-grade tirzepatide powders are not FDA-approved medicines.
Q8: What is the difference between Mounjaro and Zepbound?
Both contain tirzepatide. Mounjaro is approved for type 2 diabetes from age 10 and major cardiovascular-event risk reduction in high-risk adults with type 2 diabetes. Zepbound is approved for adult weight reduction and long-term maintenance, and moderate-to-severe OSA in adults with obesity. Maintenance choices and age-specific maximum doses differ; follow the exact product label.
Q9: What are the most common tirzepatide side effects?
Gastrointestinal effects dominate: nausea (17–22%), diarrhea (13–16%), vomiting (6–10%), decreased appetite (7–9%), and indigestion (~7%). Most are mild to moderate, hit hardest during dose escalation, and improve at stable doses. Discontinuation due to side effects ranged from ~5% at 5 mg to ~10% at 15 mg in trials. Tirzepatide also carries a boxed warning for thyroid C-cell tumors and is contraindicated with MTC or MEN 2 history.
Q10: How does tirzepatide compare to semaglutide?
Tirzepatide is a dual GIP/GLP-1 agonist; semaglutide activates GLP-1 only. In the head-to-head SURMOUNT-5 trial (NEJM 2025), tirzepatide produced −20.2% weight loss vs −13.7% for semaglutide at 72 weeks. In SURPASS-2 (T2D), all tirzepatide doses showed superior HbA1c and weight reductions vs semaglutide 1 mg. GI side-effect profiles were broadly similar.
Q11: What if I miss a tirzepatide dose?
Per the Mounjaro and Zepbound prescribing information, take the missed dose as soon as possible if it is within 4 days (96 hours). After that window, skip it and resume on the next regularly scheduled day. Do not double up. The day of the week can be changed as long as the last dose was at least 3 days earlier.
Q12: Who should not take tirzepatide?
Tirzepatide is contraindicated with a personal or family history of medullary thyroid carcinoma, MEN 2, or a serious hypersensitivity reaction to tirzepatide or its ingredients. Severe gastroparesis, pancreatitis concerns, pregnancy, and other conditions require product-specific clinician review. Zepbound should be discontinued when pregnancy is recognized. It is not a substitute for insulin in type 1 diabetes.
Q13: What vial sizes are available for research-grade tirzepatide?
Research suppliers list nominal 5, 10, 15, 40, and 60 mg vials. Vial mass affects concentration and theoretical amount counts; it does not establish identity, sterility, usable life, or equivalence to Mounjaro or Zepbound.
Q14: How is reconstituted tirzepatide stored?
No generic storage or beyond-use period for research-vial tirzepatide is established here. Use validated instructions for the exact material. A compounded preparation follows the dispensing pharmacy’s label; Mounjaro and Zepbound finished products follow their own current presentation-specific instructions. An opened water bottle has a separate discard date.
Q15: Is compounded tirzepatide the same as branded Mounjaro or Zepbound?
Compounded tirzepatide is a tirzepatide product mixed by a compounding pharmacy, not the FDA-approved Lilly pen. During the 2023–2024 shortage, large-scale compounding was permitted; outside that shortage, access is restricted and depends on state and federal compounding rules. Compounded products vary in concentration, formulation, and quality. They are not bioequivalent to Mounjaro or Zepbound by FDA standards.
Q16: Can tirzepatide be taken orally?
Not currently. As of June 2026 there is no FDA-approved oral tirzepatide. Oral incretin therapies do exist for semaglutide (Rybelsus), but tirzepatide is only FDA-approved as a subcutaneous injection. "Tirzepatide tablets" sold online are not FDA-approved formulations.
Sources & Research
- 1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine (2022)
- 2. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine (2025)
- 3. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine (2021)
- 4. Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet (2021)
- 5. Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (SURPASS-5). JAMA (2022)
- 6. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). New England Journal of Medicine (2024)
- 7. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). New England Journal of Medicine (2024)
- 8. U.S. Food and Drug Administration Mounjaro (tirzepatide) injection — Prescribing Information (revised August 2026). Eli Lilly / FDA-approved prescribing information (2026)
- 9. U.S. Food and Drug Administration Zepbound (tirzepatide) injection — Prescribing Information (revised August 2026). Eli Lilly / FDA-approved prescribing information (2026)
- 10. Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management (narrative review). Journal of Obesity & Metabolic Syndrome (2023)
- 11. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism (2018)
- 12. ClinicalTrials.gov A Study of Tirzepatide (LY3298176) on Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT, NCT04255433). ClinicalTrials.gov (2026)
Related Dosing Protocols
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: October 2026
Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.
Share this page
See our research first on Google
Add us as a preferred source for Top Stories.